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Abstract
Background: The ubiquitin-ligase Fbw7 acts as a tumor suppressor, targeting lots of proto-oncogenes
for proteolysis. However, the exact role of Fbw7 in diffuse large B-cell lymphoma (DLBCL) development
remains unclear.
Methods: We evaluated Fbw7 expression in patient samples of DLBCL using immunohistochemical staining.
The effect of Fbw7 overexpression on cell viability and apoptosis was investigated using activated B-cell (ABC)
like DLBCL cell lines. The mechanism of Fbw7 activity in DLBCL was investigated using immunoprecipitation,
ubiquitination, western blot and qualitative analyses.
Results: The non-germinal center B-cell-like subtype of DLBCL showed reduced Fbw7 expression compared with
the germinal center B-cell (GBC) subtype, and low Fbw7 expression was associated with a worse prognosis. Fbw7
overexpression caused decreased cell viability and increased apoptosis rates in the ABC-DLBCL cell lines SU-DHL-2
and OCI-LY-3. Importantly, Stat3 and phospho-Stat3Tyr705 stability were reduced following Fbw7 overexpression
in ABC-DLBCL cell lines. In HEK293T and SU-DHL-2 cells, we demonstrated that Fbw7 interacts with Stat3 and
pStat3Tyr705 to regulate their ubiquitylation and degradation. Downstream anti-apoptotic target genes of
activated Stat3, including Myc, Survivin, Mcl-1, Pim-1, Bcl-2 and Bcl-xl showed decreased mRNA expression
following exogenous Fbw7 overexpression. The negative relationship between Fbw7 and pStat3Tyr705 levels was
also confirmed in DLBCL patient samples.
Conclusion: The ubiquitin-ligase Fbw7 mediates apoptosis through targeting Stat3 for ubiquitylation and
degradation in ABC-DLBCL. Thus, our study may offer a promising approach for ABC-DLBCL therapy through
Stat3 inhibition.
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most
common type of non-Hodgkin lymphoma in adults, con-
tributing to nearly 40% of new diagnoses [1]. However,
DLBCL is involuted both in clinical presentation and
morphology. To resolve this problem, DLBCL is now
classified as GCB-DLBCL and ABC-DLBCL by genetic
profiling [2, 3], and patients with the ABC subtype show
a significantly poorer outcome compared with the GCB
subtype [4]. Immunohistochemistry (IHC) for CD10,
Bcl-6 and MUM1 can also differentiate between the
GCB and non-GCB subtypes of DLBCL and predicts
similar outcomes to genetic profiling [5]. Improved
therapies are required for all patients with DLBCL but
most urgently for those with the ABC subtype, which is
the most chemoresistant and has a worse prognosis [6].
ABC-DLBCL is associated with many different onco-
genic events, but all ultimately act on nuclear factor-κB
(NF-κB) to promote lymphomagenesis [7]. Therefore,
signal transducer and activator of transcription 3 (Stat3),
which cooperates with NF-κB signaling, is a promising
candidate for ABC-DLBCL targeted therapy [8, 9].
Stat3 is constitutively activated in various tumor types,
contributing to enhanced proliferation, survival, angio-
genesis and immune evasion via several mechanisms
[10–14]. Constitutively activated Stat3 in ABC-DLBCL
is associated with poor survival [15]; moreover, Stat3
activation is a biomarker for poor survival in DLBCL
after rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone (R-CHOP) treatment [16].
Fbw7, also known as CDC4, is a substrate recognition
element of the evolutionarily conserved SCF-type ubi-
quitin ligase complex. Acting as a tumor suppressor in
human cancer, Fbw7 substrates include several proto-
oncogenes, which are ubiquitylated and tagged for pro-
teasomal degradation [17–26]. Fbw7 genetic deletion
results in developmental defects, embryonic lethality
and genetic instability, and Fbw7 inactivation by loss
of expression or mutation is associated with tumor
development [27]. In the hematopoietic system, Fbw7
inactivation leads to hematopoietic stem cell (HSC)
depletion by active cell cycling, which can initiate
leukemia [28, 29]. Another study showed that HSC
differentiation was mediated by Fbw7 regulating Myc
stability [30]. Although Fbw7 targets various substrates
for degradation that have crucial roles in cell cycle,
apoptosis and differentiation, the role of Fbw7-mediated
degradation of such targets remains unclear.
Here, we investigate Fbw7 expression in DLBCL.
Interestingly, Fbw7 showed lower expression in the non-
GCB-DLBCL subtype compared with GCB-DLBCL. The
major phenotype associated with Fbw7 overexpression
in ABC-DLBCL cell lines was the regulation of cell
apoptosis. Furthermore, we confirmed that Fbw7 targets
Stat3 and pStat3Tyr705 for ubiquitin-dependent degrad-
ation., and the downstream anti-apoptosis target genes
of activated Stat3, including Pim1, Survivin, Mcl-1,
Myc, Bcl2 and Bcl-xl showed reduced mRNA expres-
sion following exogenous Fbw7 overexpression, in a
cell-dependent manner. Together, these results reveal
an Fbw7-dependent mechanism that regulates Stat3
ubiquitylation and degradation, providing new insight
into the tumor suppressor role of Fbw7, and suggesting




The following antibodies were used in the study: anti-
Fbw7 (for IHC) (H00055294-M02, Abnova, Taipei City,
Taiwan), anti-Fbw7 (for western blots) (ab109617,
Abcam, Cambridge, UK), anti-Stat3, 12640; anti-
phospho-Stat3Tyr705, 4113; anti-Ubiquitin, 3936 (Cell
Signaling Technology, Beverly, MA, USA), anti-Myc
tag, 16286–1-AP; anti-Flag tag, 66008–2-Ig; and anti-β-
actin, 60008–2-Ig; anti-Myc, 10828–1-AP; anti-Notch,
10062–2-AP; anti-Jun, 10024–2-AP; anti-DEK, 16448–
1-AP; anti-Mcl1, 16225–1-AP(Proteintech, Rosemont,
IL, USA). All other chemicals were purchased from
Sigma-Aldrich (St. Louis, MO, USA) and Amresco
(Dallas, TX, USA).
Cell culture
The DLBCL cell lines SU-DHL-2 and OCI-LY-3 were
cultured in RPMI-1640 supplemented with 10% fetal
bovine serum (FBS; Gibco, Carlsbad, CA, USA), and
HEK293T cells were cultured in DMEM supplemented
with 10% FBS. Cells were maintained in a humidified
chamber with 5% CO2 at 37 °C. The identity of cell lines
was confirmed by short tandem repeats-polymerase
chain reaction (STR-PCR) genotyping.
Cell transfection
Vectors containing Fbw7, Stat3 and Ubiquitin were
generated by cloning PCR amplified full-length human
cDNAs into pcDNA3.1. And the human Stat3 siRNA
target sequence was 5′-CACAT GCCAC TTTGG
TGTTT CATAA-3′. Lipofectamine 3000 (Invitrogen,
Carlsbad, CA, USA) was using to perform transfections
according to the manufacturer’s instructions.
Tissue samples and IHC
From 2005 to 2011, 165 human DLBCL samples were
collected at the Guangdong General Hospital. The study
was approved by Guangdong general hospital Biomedical
Research Ethics Committee, and written informed con-
sent was obtained from all the patients. Patients with
DLBCL have been followed up for at least 5 years with
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a intervals of 1–3 months until July 2016. The clinico-
pathological characteristics of the DLBCL patients are
showed in Additional files 1 and 2.
Samples were probed using the indicated antibodies.
Paraffin-embedded samples were made into a tissue
microarray. Staining was evaluated by two blinded indi-
viduals, and the scoring criteria was: 0 (no staining), 1
(weak staining), 2 (intermediate staining) and 3 (strong
staining). Two pathologist gave a score and the final
score was the average.
Apoptosis analysis
Cells were first transfected with an Fbw7 expression
plasmid or vector control, and then Doxorubicin (MP
Biomedicals, Illkirch-Graffenstaden France) was used to
induce apoptosis. We used the Annexin V-FITC Apop-
tosis Detection Kit (KeyGEN BioTECH, Nanjing,
China), according to the manufacturer’s instructions,
and the percentage of apoptotic cells was detected by
flow cytometry analysis.
Cell viability assay
For cell viability assay, 5 × 104 cells per well were plated
in 96-well, and then incubated with the appropriate
medium containing Doxorubicin for 24 h. Assays were
performed using the Cell Titer-Glo Luminescent Cell
Viability Assay kit (Promega, Madison, WI, USA), ac-
cording to the manufacturer’s instructions.
Western blotting
Cells were lysed in RIPA lysis buffer (0.1% SDS, 50 mM
Tris containing 150 mM NaCl, 1% Triton X-100 and 1%
sodium deoxycholate; pH 7.2) with cocktails inhibitor of
protease and phosphatase (Merck, Kenilworth, NJ, USA)
on ice for 30 min and centrifuged at 14 000 × g for
30 min. According to the protein concentration of BCA
Assay (Pierce, Rockford, IL, USA), 40 μg of protein was
loaded on 8% SDS-PAGE gels. And then protein was
transferred to PVDF membranes (Millipore, Billerica,
MA, USA). Following transfer, blots were blocked, in-
cubated with primary and secondary antibodies and
exposed to film using standard procedures.
Immunoprecipitation and ubiquitination assay
Cells were lysed in RIPA lysis buffer, and the lysates
were immunoprecipitated with the indicated antibodies
on protein A/G beads (Millipore) overnight. The beads
were then washed and boiled in SDS loading buffer.
Immunoprecipitated protein complexes were assessed
using Western blotting. To detect ubiquitination of
Stat3 and pStat3Tyr705, 10 mM N-ethylmaleimide was
added in the lysis buffer.
RNA extraction and qPCR analysis
Total RNAs were purified using RNAiso Plus, and first-
strand cDNA was generated with PrimeScript RT Master
Mix (Takara, Shiga, Japan). qPCR was carried out using
SYBR Premix Ex Taq (Takara) on an ABI 7500 PCR sys-
tem (Applied Biosystems, Carlsbad, CA, USA). The PCR
protocol was made up of 40 cycles of clocking at 95 °C
for 5 s and 60 °C for 30 s. The data was represented rela-
tive to β-actin, calculated using the 2−ΔΔCT method. The
primers for PCR reactions are listed in Additional file 3.
Statistical analysis
Statistical analyses were carried out using the SPSS 16.0
statistical software (SPSS Inc., Chicago, IL, USA). Data
are shown as mean ± SD. The relationships between
Fbw7 expression and other clinicopathological factors
were determined using Pearson χ2 test. Kaplan-Meier
survival analysis was applied to illustrate the outcome
relevance of Fbw7 in univariate analysis. Each assay was
performed in three repeated experiments. The Student t
test was used to compare two groups of independent
samples. Correlations between Fbw7 and pStat3Tyr705
levels were confirmed using the Spearman rank correl-
ation. Values of P < 0.05 were considered significant.
Results
Decreased Fbw7 expression in non-GCB DLBCL
compared with GCB-DLBCL is significantly correlated
with poor survival
To investigate the role of Fbw7 in DLBCL, Fbw7 expres-
sion was first analyzed in DLBCL through IHC. Using
the Hans program [5], 165 patients were divided into
two groups (non-GCB and GCB) based on CD10, Bcl-6
and MUM1 expression by IHC during the clinical diag-
nosis of pathology; representative IHC images of GCB
and non-GCB are shown (Fig. 1a). IHC showed that
Fbw7 expression was decreased in the non-GCB group
compared with the GCB group (P < 0.01; Fig. 1b). Low
Fbw7 expression and high expression cases were shown
(Fig. 1c). The correlation between Fbw7 expression and
other clinicopathological features, such as patient sex,
age, EB virus status and tumor stage showed no signifi-
cant differences (P > 0.05; Additional file 1). Kaplan-
Meier analysis indicated that patients with low Fbw7
expression showed a significantly worse outcome com-
pared with those with high Fbw7 expression (Fig. 1d).
The median survival time of DLBCL patients with low
Fbw7 expression was 44 months, which was signifi-
cantly shorter than those with high Fbw7 expression
(81 months). Together, these results clearly show that
Fbw7 expression is decreased in non-GCB-DLBCL
compared with GCB-DLBCL, and low Fbw7 expression
is associated with a worse prognosis.
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Fbw7 regulates apoptosis in ABC-DLBCL
Based on the Hans algorithm, IHC can be used to differ-
entiate the GCB and non-GCB subtypes of DLBCL, and
this predicts survival similar to genetic profiling (GCB and
ABC subtypes). The prevalence of Fbw7 downregulation
in non-GCB subtype raises an intriguing possibility that
Fbw7 overexpression may be a tumor-inhibiting event in
ABC-DLBCL. To test this possibility, the ABC-DLBCL
cell lines SU-DHL-2 and OCI-LY-3 were transfected with
an Fbw7 expression plasmid, and western blotting con-
firmed that Fbw7 expression was greatly increased after
transfection (Fig. 2a). Next, we investigated how Fbw7 af-
fects the apoptotic response using Doxorubicin to induce
apoptosis. To detect the percentage of apoptotic cells, we
stained with Annexin-V-PE followed by flow cytometry
analysis. As predicted, SU-DHL-2 and OCI-LY-3 cell lines
were more sensitive to apoptotic stimuli after transfecting
an Fbw7 plasmid compared with vector (Fig. 2b). To in-
vestigate the tumor inhibitory effect of Fbw7 in ABC-
DLBCL, cells were transfected with the Fbw7 plasmid or
vector and treated with Doxorubicin at different concen-
trations. As expected, cell viability decreased significantly
in the Fbw7 overexpression group compared with the
vector group (Fig. 2c). Although it’s reported that Fbw7
also regulates proliferation by suppressing tumorigenesis
in many cancers, our results of CCK8 assays and cell cycle
showed no significant difference after Fbw7 overexpres-
sion in ABC-DLBCL cell lines (Additional file 4).
Fbw7 regulates the stability of Stat3
Previous studies have shown that Stat3 is constitutive ac-
tivated in ABC-DLBCL, causing us to evaluate whether
Fbw7 regulates Stat3 expression or activity. SU-DHL-2
and OCI-LY-3 cells were transfected with Fbw7 and
Stat3 plasmids, and western blotting indicated that Fbw7
decreased the exogenous Stat3 protein level (Fig. 3a).
Similarly, Fbw7 overexpression markedly decreased en-
dogenous Stat3 and pStat3Tyr705 levels in a dose-
dependent manner (Fig. 3b). To investigate whether and
how Fbw7 regulates Stat3 stability, SU-DHL-2 cells were
treated with an inhibitor of protein synthesis cyclohexi-
mide (CHX), and the stability of endogenous Stat3 and
pStat3Tyr705 was examined. The half-life of pStat3Tyr705
decreased from 9 h to approximately 5 h upon Fbw7
overexpression (Fig. 3c). Similarly, Fbw7 overexpression
in OCI-LY-3 cells significantly reduced pStat3Tyr705
levels (Fig. 3d). These results reveal that Fbw7 reduced
Stat3 signaling by promoting its degradation.
Fig. 1 Fbw7 shows reduced expression in non-GCB DLBCL. a for 165 cases of DLBCLs, the classification of GCB and non-GCB groups was previously
confirmed by clinical IHC of CD10, Bcl-6 and MUM1; representative IHC cases from GCB and non-GCB patients are shown. b bar chart of Fbw7
expression in the GCB (n = 43) and non-GCB (n = 122) groups. Statistical significance was determined by a two-tailed, Student t test. **, P < 0.01.
c IHC staining of Fbw7 in DLBCL, “score ≤ 1” was defined as the low expression group and “score > 1” was defined as the high expression group.
Low Fbw7 expression and high Fbw7 expression cases were shown. d Kaplan-Meier survival curve shows a significant association between low
Fbw7 levels and poor survival in DLBCL patients (P = 0.004). Low Fbw7 (n = 30), high Fbw7 (n =134) and missing follow-up (n = 1)
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Fbw7 targets Stat3 for ubiquitylation
Next, we investigated the ability of Fbw7 to interact with
Stat3. Myc-Fbw7 and Flag-Stat3 were co-expressed in
HEK293T cells. Co-immunoprecipitation analysis showed
that Stat3 co-immunoprecipitated with Myc-Fbw7 by
anti-Myc antibody (Fig. 4a, top). Similarly, immunopre-
cipitation of Flag-Stat3 by anti-Flag antibody led to co-
immunoprecipitation of Myc-Fbw7 (Fig. 4a, bottom).
Endogenous Fbw7 and Stat3 were immunoprecipitated
from SU-DHL-2 cells and the presence of endogenous
Stat3 and Fbw7 was detected, respectively (Fig. 4b).
Similarly, endogenous Fbw7 and pStat3Tyr705 were
immunoprecipitated from SU-DHL-2 cells, and the
presence of endogenous pStat3Tyr705 and Fbw7 was
detected, respectively (Fig. 4c). Similar results were
obtained in HEK293T cells (Additional file 5). Together,
these results show that Fbw7 can interact with Stat3 and
pStat3Tyr705.
Fbw7 is a ubiquitin-ligase that targets several proteins
for ubiquitination and degradation. Therefore, we then
speculated that Fbw7 might directly regulate Stat3 stability
through this activity. To assess this possibility, Flag-Stat3
and HA-ubiquitin were co-expressed with and without
Myc-Fbw7 in HEK293T cells. Immunoblotting showed
that ubiquitination of Stat-3, and especially pStat3Tyr705,
strongly increased after Fbw7 expression in the presence
or absence of MG132, an inhibitor of the 26S proteasome
(Fig. 4d and e). Immunoblotting showed similar results for
Fig. 2 Fbw7 overexpression promotes apoptosis in ABC-DLBCL. a Western blot showing increased Fbw7 expression in the ABC-DLBCL cell lines
SU-DHL-2 and OCI-LY-3 after transfection with Fbw7 expression plasmid for 48 h. b Annexin-V–PE staining, followed by flow cytometry analysis to
detect the percentage of apoptotic cells. In the indicated ABC-DLBCL cell lines, Fbw7 was upregulated by transfection (pcDNA3.1 vector was used
as a negative control) for 24 h. Cell lines were cultured with Doxorubicin (1.0 μM) for 24 h to induce apoptosis before flow cytometry. Statistical
significance was determined by a two-tailed, paired Student t test. **, P < 0.01; ***, P < 0.001. c Cell viability assays show that ABC-DLBCL cell lines
were more sensitive to Doxorubicin after transfection with Fbw7 plasmid. ABC-DLBCL cells with 24 h exogenous Fbw7 expression were cultured
with the indicated concentrations of Doxorubicin for 24 h before cell viability assays were performed. Statistical significance was determined by a
two-tailed Student t test. ***, P < 0.001. Data are presented as mean ± SD from three independent experiments
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pStat3Tyr705 ubiquitination after cells were treated with IL-
6 cytokines (Fig. 4e). These results conclusively indicate
that Fbw7 regulates Stat3 protein levels through ubiquiti-
nation and proteasomal degradation.
Fbw7 inhibits apoptosis regulators downstream of Stat3
Constitutively active Stat3 signaling leads to the upregula-
tion of many downstream target genes in ABC-DLBCL,
and our data indicate that Fbw7 could inhibit the expres-
sion of these genes through degradation of activated Stat3.
To test this hypothesis, SU-DHL-2 and OCI-LY-3 cells
were transduced with Fbw7 plasmid, and by qPCR showed
upregulation of Fbw7 mRNA at the indicated time points
(Fig. 5a). No significant change in Stat3 mRNA levels were
detected (Fig. 5b), demonstrating that Fbw7 did not affect
Stat3 mRNA. However, qPCR revealed that Fbw7 overex-
pression resulted in a downregulation of several Stat3
target genes that regulate apoptosis, in a cell-dependent
manner (Fig. 5c). Results showed a significant reduction in
Survivin, Pim-1 and Bcl-2 mRNA levels in SU-DHL-2
cells (right), as well as a significant reduction in Myc, Sur-
vivin, Mcl-1, Bcl-2 and Bcl-xl mRNA levels in OCI-LY-3
cells (left). Thus, our results suggest that Fbw7 promotes
apoptosis by downregulating these anti-apoptotic genes
in ABC-DLBCL.
To demonstrate whether Fbw7 promotes apoptosis
through regulating Stat3, siRNA of Stat3, plasmids of
Fbw7 and Stat3 was transfected as instructed in ABC-
DLBCL cell lines, using Doxorubicin to induce apoptosis
and staining with Annexin-V-PE followed by flow cytome-
try analysis. As predicted, SU-DHL-2 and OCI-LY-3 cell
lines were more sensitive to apoptotic stimuli after trans-
fecting siRNA of Stat3 or Fbw7 plasmid compared with
control groups, and co-expression of Stat3 and Fbw7 plas-
mids reversed apoptosis compared with Fbw7 groups.
Fbw7 expression is negatively correlated with pStat3Tyr705
levels in DLBCL patient samples
To further evaluate the relationship between Fbw7 and
Stat3, the expression of Fbw7 and Stat3 was analyzed in
56 cases of DLBCL. IHC staining showed that high
Fbw7 expression was associated with low pStat3Tyr705
expression in Case 1. Inversely, low Fbw7 expression
was associated with high pStat3Tyr705 levels in Case 2
(Fig. 6a). Spearman rank correlation analysis further
confirmed that Fbw7 expression was negatively associ-
ated with pStat3Tyr705 expression (Fig. 6b). These results
demonstrated that high Fbw7 expression was associated
with reduced levels of active Stat3 in human tumor
samples, supporting our in vitro data.
Fig. 3 Fbw7 reduces the stability of Stat3. a western blotting of exogenous Stat3 in SUDHL-2 and OCI-LY-3 cells co-expressing Fbw7. b Fbw7
upregulation decreases endogenous Stat3 and especially pStat3Tyr705 expression. c and d, Fbw7 decreases the stability of Stat3 and pStat3Tyr705.
Myc-Fbw7 was transfected into SUDHL-2 and OCI-LY-3 cells. After treating cells with cycloheximide (CHX; 10 mg/ml) for the indicated time intervals,
Fbw7, Stat3 and pStat3Tyr705 levels were examined by immunoblotting (top). Western blots were quantified via densitometry, and the mean ratios of
the indicated proteins from three independent experiments are shown at the bottom of the figure. Data are shown as mean ± SD in the line graph
for three independent experiments. Statistical significance was determined by a two-tailed unpaired Student t test. ***, P < 0.001
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Discussion
The ubiquitin-ligase Fbw7 targets several proto-
oncogenes for ubiquitination and degradation and acts
as a tumor suppressor in many human malignancies.
However, the Fbw7 substrates that have important roles in
the development of specific cancers are unknown. Here,
we investigated Fbw7 in ABC-DLBCL and found that
Fbw7 targets Stat3 for ubiquitylation and degradation, and
that Fbw7 inhibits downstream anti-apoptotic targets of
Stat3.
DLBCL is attributable for nearly 40% of all non-
Hodgkin lymphoma diagnoses and has been divided into
the molecular subtypes GCB and ABC by genetic profil-
ing. Overall survival is significantly reduced in the ABC-
DLBCL compared with the GCB-DLBCL. In our study,
we found that Fbw7 expression was reduced in DLBCL
associated with the ABC subtype (Fig. 1b). Low Fbw7
expression also correlated with a poor prognosis (Fig. 1d).
We also demonstrate that Fbw7 is an apoptosis regulator
through flow cytometry analysis and cell viability assays
(Fig. 2b and c). Previous studies have shown that Fbw7
targets c-Jun and Mcl-1, regulating apoptosis [18, 20],
and these data interested us to investigate its molecular
mechanism for regulating apoptosis in ABC-DLBCL.
Stat3, an important transcript factor in many human
cancers, shows a high level of expression and activation
in ABC-DLBCL [15]. Constitutive Stat3 activation is also
a biomarker for poor prognosis after R-CHOP therapy
[16]. Previous studies demonstrated Stat3 siRNA or kin-
ase inhibitors reduced tumor proliferation in vitro [31].
These reports suggest targeting Stat3 could be a prom-
ising approach to therapy in ABC-DLBCL. Our data
confirmed Fbw7 targets Stat3 for ubiquitylation and
degradation, especially Stat3 phosphorylated at tyrosine
705. First, we found Fbw7 influenced the stability of
Stat3 and pStat3Tyr705 in a dose-dependent manner
(Fig. 3b). Further, we showed that Fbw7 interacts with
Stat3 and pStat3Tyr705 in ABC-DLBCL cells by co-
immunoprecipitation (Fig. 4a-c). Moreover, Fbw7 inter-
acts with Stat3 and pStat3Tyr705 to regulate their
Fig. 4 Fbw7 interacts with and ubiquitinates Stat3. a Fbw7 interacts with Stat3 at exogenous levels. Immunoblotting analysis of lysates after
immunoprecipitation from HEK293T cells transfected with Myc-Fbw7 and Flag-Stat3. b Fbw7 interacts with Stat3 at endogenous levels. Cell lysates
from SU-DHL-2 cells were immunoprecipitated with anti-Fbw7 or anti-Stat3 antibody, followed by immunoblotting with anti-Fbw7 or anti-Stat3
antibody, respectively. IgG was used as a control. c Fbw7 interacts with pStat3Tyr705 at endogenous levels. Cell lysates from SU-DHL-2 cells were
immunoprecipitated with anti-Fbw7 or anti-pStat3Tyr705 antibody, followed by immunoblotting with anti-Fbw7 or anti- pStat3Tyr705 antibody,
respectively. d and e, Flag-Stat3 and HA-ubiquitin were co-expressed with Myc-Fbw7 in HEK293T cells. After cells were treated with or without
10 mM MG132 for 6 h, Stat3 and pStat3Tyr705 were immunoprecipitated with anti-Flag or anti-pStat3Tyr705 antibody, and the polyubiquitination
status of Stat3 and pStat3Tyr705 was detected by immunoblotting. f similar to E, cells were treated with 10 ng/L IL6 for 6 h to activate Stat3
signaling. The experiments were repeated three times, and representative images of blots are shown
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ubiquitylation and degradation. It has been reported
that Fbw7 binds to its substrates after they have been
phosphorylated within conserved phospho-degron mo-
tifs, called Cdc4 phospho-degrons (CPDs) [32]. Several
studies have demonstrated that Fbw7 targets phosphor-
ylated substrates, including Myc, c-Jun, Mcl-1, Notch
and KLF2 [17, 18, 20–22]. The ability of Fbw7 to de-
grade these oncogenes, specifically, makes it a tumor
suppressor. Our results showed that Fbw7 interacts
with and degrades Stat3 in ABC-DLBCL, and therefore;
may be a viable target for Stat3-directed therapy.
Stat3 is required for tumor cell proliferation, infiltra-
tion, differentiation and apoptosis inhibition. Stat3 is ac-
tivated by phosphorylation, which produces a molecule
that spontaneously dimerizes, binds to DNA and acti-
vates transcription of downstream target genes [10, 11],
Fig. 5 Fbw7 inhibits downstream Stat3 target genes that block apoptosis. a-d, qPCR analysis of the relative mRNA expression in ABC-DLBCL cell
lines at the indicated time intervals. mRNA levels were normalized to the geometric mean of the housekeeping gene β-actin and calculated using the
2−ΔΔCT method. The experiments were repeated three times. Statistical analysis was performed using a two-tailed unpaired Student t test.*, P < 0.05; **,
P < 0.01; ***, P < 0.001. a (right), cells were transfected with Fbw7 and compared with vector control to detect Fbw7 expression. b (left), cells were
transfected with Fbw7 and compared with vector control to detect Stat3 expression. c and d, qPCR analysis of the relative Myc, Survivin, Mcl-1,
Pim-1, Bcl-2 and Bcl-xl mRNA levels after transfecting Fbw7 for 48 h in SU-DHL-2 and OCI-LY-3 cells, respectively. e siRNA of Stat3, plasmids of
Fbw7 and Stat3 was transfected as instructed for 24 h in ABC-DLBCL cell lines. And then cell lines were cultured with Doxorubicin (1.0 μM) for
24 h to induce apoptosis before flow cytometry. Statistical significance was determined by a two-tailed, unpaired Student t test. ***, P < 0.001
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some of which block apoptosis, including Myc, Survivin,
Bcl-2, Mcl-1, Pim-1 and Bcl-xl [33–36]. Our results also
revealed that Fbw7 overexpression reduced mRNA levels
of these target genes in a cell-dependent manner in
ABC-DLBCL cell lines. There was a significant reduction
in Survivin, Pim-1 and Bcl-2 mRNA levels in SU-DHL-2
cells (Fig. 5c, right), as well as a significant reduction in
Myc, Survivin, Mcl-1, Bcl-2 and Bcl-xl mRNA levels in
OCI-LY-3 cells (Fig. 5c, left). Thus, both our clinical and
experimental data suggest Fbw7 regulates Stat3 stability
and downstream signaling, making it a promising target
for therapy. Although it is well known that cyclin D1 is
the target gene of Stat3 which regulates cell proliferation
and cell cycle, qPCR revealed that Fbw7 overexpression
did not result in significant reduction of cyclin D1
(Additional file 6). And the results of CCK8 prolifera-
tion assays and cell cycle did not show significant dif-
ference after Fbw7 overexpression in ABC-DLBCL cell
lines (Additional file 4). It’s reported that only 2.1% of
patients in total of 1435 express cyclin D1 in DLBCL
[37]. Therefore our negative results of cyclin D1 may
be related to its missing expression. Moreover, Fbw7-
induced degradation of STAT3 is more important than
other reported tumorigenesis including Myc, Notch,
Jun, DEK and MCL1 in ABC-DLBCL (Additional file 7).
Fbw7 regulates a proliferative network that includes
several oncogenes, and therefore, is considered a tumor
suppressor in human cancers. There may be a viable
approach for therapies directed at Fbw7 and its sub-
strates. Studies have shown that Fbw7 expression is reg-
ulated by upstream proteins including p53, EBP2,
Numb4, Pin1 and Hes-5 [38–41]. In addition, multiple
microRNAs, including miR-25, miR-129-5p and miR-
223 have also been demonstrated to regulate Fbw7 ex-
pression [42–44]. Together, these factors comprise a
complex regulatory network that controls Fbw7 expres-
sion. However, exploiting this regulatory network for a
means to restore or increase Fbw7 expression requires a
deeper understanding of its transcriptional and post-
transcriptional regulation. Further research into the up-
stream pathways that phosphorylate Stat3, marking it for
Fbw7-mediated ubiquitylation, could also be a promising
approach for drug discovery in ABC-DLBCL.
Conclusions
In this study, we investigated the role of Fbw7 in ABC-
DLBCL, and found it showed reduced expression in
non-GCB DLBCL, which was associated with a poor
outcome. Fbw7 expression promotes apoptosis in ABC-
DLBCL cell lines. Furthermore, we demonstrated that
Fbw7 targets Stat3 and especially activated Stat3 for ubi-
quitylation to regulate its stability. QPCR analysis also
demonstrated that the downstream target genes of Stat3
which mediate anti-apoptotic effects were downregu-
lated following Fbw7 expression in ABC-DLBCL. To-
gether, our data clearly show that the ubiquitin-ligase
Fig. 6 Fbw7 expression negatively correlates with Stat3 expression in DLBCL cell lines and clinical DLBCL samples. a IHC staining of Fbw7 and
pStat3Tyr705 in human DLBCL tissues. Representative images of IHC staining from the same tumor samples are shown. b Spearman correlation
analysis between Fbw7 and pStat3Tyr705 in 56 cases of DLBCL tissues. c schematic representation of the function and potential mechanism of
Fbw7 in ABC-DLBCL
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Fbw7 targets Stat3 for ubiquitylation and degradation
to regulate apoptosis in ABC-DLBCL, and our study
may offer a promising approach for therapy by offering
a new method of Stat3 inhibition.
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